BioNTech SE
BioNTech to Establish Regional Headquarters for South East Asia and First mRNA Manufacturing Facility in Singapore
BioNTech to Establish Regional Headquarters for South East Asia and First mRNA Manufacturing Facility in Singapore
BioNTech to establish first regional hub in Asia Pacific region in Singapore
Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats
Expansion plan supported by the Singapore Economic Development Board (EDB)
MAINZ, GERMANY, May 10, 2021
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manu
FILE PHOTO: A healthcare worker prepares a dose of the Pfizer/BioNTech coronavirus disease (COVID-19) vaccine, which was authorized by Canada to be used for children aged 12 to 15, at Woodbine Racetrack pop-up vaccine clinic in Toronto, Ontario, Canada May 5, 2021. REUTERS/Carlos Osorio SINGAPORE: BioNTech SE today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for southeast Asia in Singapore.
The German biotechnology company also plans to establish a fully integrated messenger RNA (mRNA) manufacturing facility in the republic with support from the Singapore Economic Development Board. Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” said its Chief Executive and Co-founder, Ugur Sahin, in its website.
Article by Amanda Doyle
BIONTECH has announced that it will build an mRNA manufacturing facility in Singapore as well as establish its regional headquarters for Southeast Asia there.
BioNTech, in partnership with Pfizer, has developed an mRNA Covid-19 vaccine. It is also developing patient-specific cancer immunotherapies. It currently has more than 20 product candidates with ten candidates in ongoing clinical trials.
The new manufacturing facility will be established with support from the Singapore Economic Development Board.
The facility will have highly automated mRNA production capabilities for drug substance, drug product, and fill-and-finish. It will be able to produce a range of mRNA vaccines and therapeutics for infectious diseases and cancer, and will have a production capacity of several hundred million mRNA doses depending on the vaccine. It will provide regional and global supply capacity for BioNTech’s mRNA-based product candidates and will also enable a rapid respo
Fosun, BioNTech in $200 Million China Vaccine Venture
Fosun Pharma announced that it plans to set up a joint venture with German vaccine company Biontech to achieve commercial local production of mRNA neocoronal vaccine products, with an annual capacity of 1 billion doses, on May 9.
Fosun Pharma announced it would set up a Shanghai facility to co-produce a Covid-19 vaccine developed by BioNTech SE for the China market, just hours before the German drug maker announced its own plans to build a regional headquarters and similar wholly owned facility in Singapore.
Announcement of the Shanghai facility marks the latest step in a partnership formed by Fosun and BioNTech early in the pandemic, with an aim of bringing the German company’s innovative and highly effective mRNA vaccine technology to China. Establishment of the Singapore hub is also a nod to the region’s big growth potential, and the importance of producing BioNTech’s vaccines as close as possible to their actual plac
Published: May 10, 2021
BioNTech to establish first regional hub in Asia Pacific region in Singapore
Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats
Expansion plan supported by the Singapore Economic Development Board (EDB)
MAINZ, GERMANY, May 10, 2021
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, a